{"id":8812,"date":"2021-09-07T12:51:01","date_gmt":"2021-09-07T05:51:01","guid":{"rendered":"https:\/\/www.nxpo.or.th\/th\/?p=8812"},"modified":"2021-09-07T12:51:04","modified_gmt":"2021-09-07T05:51:04","slug":"future-talk-by-nxpo-with-baiya-phytopharm-co-founders","status":"publish","type":"post","link":"https:\/\/www.nxpo.or.th\/th\/en\/8812\/","title":{"rendered":"Future Talk by NXPO with Baiya Phytopharm Co-founders"},"content":{"rendered":"\n

Future Talk by NXPO recently featured a university startup – Baiya Phytopharm – in the race of COVID-19 vaccine development. Guest speakers were two co-founders: CEO Dr. Suthira Taychakhoonavudh and CTO Dr. Waranyoo Phoolcharoen. Both are pharmaceutical sciences faculty members at Chulalongkorn University. <\/p>\n\n\n\n

\"A<\/figure><\/div>\n\n\n\n

Baiya Phytopharm is a plant-based pharmaceutical company utilizing BaiyaPharming\u2122 protein expression platform to produce recombinant molecular proteins from tobacco leaves. In the case of COVID-19 vaccine development, low-nicotine tobacco plant was engineered to produce SARS-CoV-2 viral protein. The plant-produced protein is delivered into the body to allow the body creating a specific immune system against the COVID-19 virus. The vaccine candidate, Baiya SARS-CoV-2 Vax 1, is successfully tested in animal studies (mice and monkeys) and phase I human trial will start later this month. The company also finished setting up the first plant-based vaccine and biologics manufacturing facility in Asia and is working on the second-generation COVID-19 vaccine with improved immunogenicity. The co-founders expected that the vaccines will be ready for use in the third quarter of 2022. <\/p>\n\n\n\n

Dr. Suthira revealed the challenges of running a vaccine production company that it requires multi-disciplinary knowledge including pharmacy, industrial-scale production, quality assurance, animal testing and vaccine registration. However, the blessing of having a company is to serve as a learning site for their students. Students can work in the company lab and even pitch a project to the company. In addition to practicing their scientific techniques, students also get inspired to be more entrepreneurial, which can lead to many more tech startups for Thailand. <\/p>\n\n\n\n

As for the future outlook, the co-founders have a number of drug and vaccine projects in minds. The experience and expertise gained from COVID-19 vaccine development will help expedite their future projects. They would like to see the company thrives in order to improve heath security for the Thai people. <\/p>\n\n\n\n

NXPO President Dr. Kitipong Promwong concluded the session by introducing various initiatives that NXPO has implemented to improve an innovation ecosystem. These include new measures and regulations to promote public-private joint investment, university holding company program and Thai Bayh Dole Act. NXPO is working with the Innovation Club in revising regulations to facilitate fundraising for startups. <\/p>\n","protected":false},"excerpt":{"rendered":"

Future Talk by NXPO recently featured a university star […]<\/p>\n","protected":false},"author":1,"featured_media":8814,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-8812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"featured_image_src":"https:\/\/www.nxpo.or.th\/th\/wp-content\/uploads\/2021\/09\/image-3.jpeg","author_info":{"display_name":"admin","author_link":"https:\/\/www.nxpo.or.th\/th\/author\/adminsti\/"},"jetpack_featured_media_url":"https:\/\/www.nxpo.or.th\/th\/wp-content\/uploads\/2021\/09\/image-3.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/posts\/8812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/comments?post=8812"}],"version-history":[{"count":1,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/posts\/8812\/revisions"}],"predecessor-version":[{"id":8815,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/posts\/8812\/revisions\/8815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/media\/8814"}],"wp:attachment":[{"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/media?parent=8812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/categories?post=8812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nxpo.or.th\/th\/wp-json\/wp\/v2\/tags?post=8812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}